DK3095458T3 - Farmaceutisk sammensætning til behandling af cancer omfattende trypsinogen og chymotrypsinogen - Google Patents

Farmaceutisk sammensætning til behandling af cancer omfattende trypsinogen og chymotrypsinogen Download PDF

Info

Publication number
DK3095458T3
DK3095458T3 DK16174383.6T DK16174383T DK3095458T3 DK 3095458 T3 DK3095458 T3 DK 3095458T3 DK 16174383 T DK16174383 T DK 16174383T DK 3095458 T3 DK3095458 T3 DK 3095458T3
Authority
DK
Denmark
Prior art keywords
cells
cell
chymotrypsinogen
trypsinogen
cancer
Prior art date
Application number
DK16174383.6T
Other languages
English (en)
Inventor
Julian Norman Kenyon
Paul Rodney Clayton
David Tosh
Fernando Felquer
Ralf Brandt
Original Assignee
Propanc Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905147A external-priority patent/AU2009905147A0/en
Application filed by Propanc Pty Ltd filed Critical Propanc Pty Ltd
Application granted granted Critical
Publication of DK3095458T3 publication Critical patent/DK3095458T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (9)

  1. FARMACEUTISK SAMMENSÆTNING TIL BEHANDLING AF CANCER OMFATTENDE TRYPSINOGEN OG CHYMOTRYPSINOGEN
    1. Farmaceutisk sammensætning, der omfatter trypsinogen og chymotrypsinogen, hvor vægtforholdet mellem chymotrypsinogen og trypsinogen er 4:1, 8:1 eller i området mellem 4:1 og 8:1.
  2. 2. Farmaceutisk sammensætning ifølge krav 1, hvor sammensætningen ikke indeholder amylase.
  3. 3. Farmaceutisk sammensætning ifølge krav 1 eller 2, hvor vægtforholdet mellem chymotrypsinogen og trypsinogen er mellem 5:1 og 7:1.
  4. 4. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 3, hvor vægtforholdet mellem chymotrypsinogen og trypsinogen er 6:1.
  5. 5. Farmaceutisk sammensætning, der omfatter trypsinogen og chymotrypsinogen, til anvendelse i en fremgangsmåde til behandling af cancer, hvor vægtforholdet mellem chymotrypsinogen og trypsinogen er 4:1, 8:1 eller i området mellem 4:1 og 8:1.
  6. 6. Farmaceutisk sammensætning til anvendelse ifølge krav 5, hvor sammensætningen ikke indeholder amylase.
  7. 7. Farmaceutisk sammensætning til anvendelse ifølge krav 5 eller 6, hvor vægtforholdet mellem chymotrypsinogen og trypsinogen er mellem 5:1 og 7:1.
  8. 8. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 5 til 7, hvor vægtforholdet mellem chymotrypsinogen og trypsinogen er 6:1.
  9. 9. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 5 til 8, hvor canceren er valgt fra gruppen bestående af ovariecancer, koloncancer, tarmcancer, prostatacancer, mavecancer, malignt melanom, pankreascancer, øsofaguscancer, lungecancer og brystcancer.
DK16174383.6T 2009-10-22 2010-10-22 Farmaceutisk sammensætning til behandling af cancer omfattende trypsinogen og chymotrypsinogen DK3095458T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009905147A AU2009905147A0 (en) 2009-10-22 Pharmaceutical Compositions
AU2010902655A AU2010902655A0 (en) 2010-06-17 Cancer Cell Regulation
EP10824316A EP2490711A4 (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITION FOR CREATING TREATMENT WITH TRYPSINOGENES AND / OR CHYMOTRYPINOGENS AND AN ACTIVE COMPOUNDS SELECTED FROM A SELENIC COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIDE DEDICATOR

Publications (1)

Publication Number Publication Date
DK3095458T3 true DK3095458T3 (da) 2018-11-19

Family

ID=43899732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16174383.6T DK3095458T3 (da) 2009-10-22 2010-10-22 Farmaceutisk sammensætning til behandling af cancer omfattende trypsinogen og chymotrypsinogen

Country Status (22)

Country Link
US (4) US9636359B2 (da)
EP (2) EP2490711A4 (da)
JP (1) JP5871805B2 (da)
KR (1) KR101936439B1 (da)
CN (2) CN102639145B (da)
AU (1) AU2010310887B9 (da)
BR (1) BR112012009521B1 (da)
CA (1) CA2814958C (da)
CL (1) CL2012001019A1 (da)
DK (1) DK3095458T3 (da)
ES (1) ES2692377T3 (da)
HK (1) HK1249017A1 (da)
IL (1) IL219216A (da)
MX (1) MX355971B (da)
NZ (1) NZ599996A (da)
PE (1) PE20121709A1 (da)
PT (1) PT3095458T (da)
RU (1) RU2012120785A (da)
SG (1) SG10201406651PA (da)
TR (1) TR201815315T4 (da)
WO (1) WO2011047434A1 (da)
ZA (1) ZA201203689B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639145B (zh) 2009-10-22 2017-09-26 普罗潘克股份有限公司 包含胰蛋白酶原和/或糜蛋白酶原和选自硒化合物，类香兰素化合物和细胞质糖酵解减少剂的活性剂的用于治疗癌的药物组合物
US9833486B2 (en) * 2013-03-15 2017-12-05 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
CZ307195B6 (cs) 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
MX2016011897A (es) * 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
US20160106687A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
AU2016353539B2 (en) * 2015-11-12 2020-04-23 Propanc Pty Ltd Proenzyme composition
DK3407909T3 (da) 2016-01-29 2023-11-13 Propanc Pty Ltd Cancerbehandling
EP3442564B1 (en) 2016-04-12 2023-12-06 Propanc Pty Ltd Composition of proenzymes for cancer treatment
EP3517117A1 (en) 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection
WO2022261440A1 (en) * 2021-06-11 2022-12-15 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of pancreatic cancer
EP4389913A1 (en) * 2022-12-23 2024-06-26 Universität Heidelberg A pcr-elisa analogous antibody-free method for detecting a target nucleic acid in a sample

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) * 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FR2727107B1 (fr) * 1994-11-21 1996-12-27 Saint Gobain Vitrage Vitrage muni d'au moins une couche mince et son procede d'obtention
CZ283972B6 (cs) 1995-05-17 1998-07-15 František Mudr. Trnka Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití
CN1121218C (zh) * 2000-03-08 2003-09-17 台湾东洋药品工业股份有限公司 酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
CN1471925A (zh) * 2002-08-02 2004-02-04 丛繁滋 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法
JP2004182674A (ja) * 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物
KR20050098244A (ko) * 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
US20050026852A1 (en) * 2003-05-13 2005-02-03 Rustum Youcef M. Method of augmenting the antitumor activity of anticancer agents
DE10321725A1 (de) * 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke
CN1557482A (zh) * 2004-02-04 2004-12-29 高春平 调节免疫功能、抗肿瘤的天然营养剂
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
CN101287481A (zh) * 2005-05-26 2008-10-15 科学工业研究委员会 用于治疗肝细胞癌的药物组合物
KR100740989B1 (ko) 2005-07-22 2007-07-19 넨시스(주) 구형 항염·항암효소 과립제 및 이의 제조방법
CN1944641B (zh) * 2006-10-26 2010-11-03 上海林叶生物科技有限公司 高纯度糜蛋白酶的制备方法
US9381168B2 (en) * 2007-11-09 2016-07-05 Catholic University Industry Academy Cooperation Foundation Use of capsiate or dihydrocapsidate
CN102639145B (zh) 2009-10-22 2017-09-26 普罗潘克股份有限公司 包含胰蛋白酶原和/或糜蛋白酶原和选自硒化合物，类香兰素化合物和细胞质糖酵解减少剂的活性剂的用于治疗癌的药物组合物
CZ307195B6 (cs) * 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů

Also Published As

Publication number Publication date
BR112012009521B1 (pt) 2021-07-13
US10350239B2 (en) 2019-07-16
PT3095458T (pt) 2018-11-09
WO2011047434A1 (en) 2011-04-28
EP3095458B1 (en) 2018-07-25
US20230137573A1 (en) 2023-05-04
HK1249017A1 (zh) 2018-10-26
KR20120128124A (ko) 2012-11-26
US20180064753A1 (en) 2018-03-08
KR101936439B1 (ko) 2019-01-08
ES2692377T3 (es) 2018-12-03
NZ599996A (en) 2014-06-27
CN102639145B (zh) 2017-09-26
CA2814958C (en) 2023-09-26
US9636359B2 (en) 2017-05-02
EP2490711A1 (en) 2012-08-29
AU2010310887B2 (en) 2015-09-03
AU2010310887A1 (en) 2012-06-07
CN107625957A (zh) 2018-01-26
SG10201406651PA (en) 2014-11-27
CL2012001019A1 (es) 2013-07-12
US20190388463A1 (en) 2019-12-26
JP2013508307A (ja) 2013-03-07
IL219216A (en) 2017-03-30
CN102639145A (zh) 2012-08-15
BR112012009521A2 (pt) 2016-05-17
CA2814958A1 (en) 2011-04-28
JP5871805B2 (ja) 2016-03-01
MX2012004610A (es) 2012-11-12
PE20121709A1 (es) 2012-12-17
TR201815315T4 (tr) 2018-11-21
EP2490711A4 (en) 2013-04-03
MX355971B (es) 2018-05-07
IL219216A0 (en) 2012-06-28
AU2010310887B9 (en) 2015-10-08
ZA201203689B (en) 2013-02-27
EP3095458A1 (en) 2016-11-23
US20120251516A1 (en) 2012-10-04
CN107625957B (zh) 2021-06-15
RU2012120785A (ru) 2013-11-27

Similar Documents

Publication Publication Date Title
US20230137573A1 (en) Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent
Jin et al. Morin, a flavonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB‑231 partly through suppression of the Akt pathway
Pitchakarn et al. Ellagic acid inhibits migration and invasion by prostate cancer cell lines
Kim et al. Ethanol extract of Ocimum sanctum exerts anti-metastatic activity through inactivation of matrix metalloproteinase-9 and enhancement of anti-oxidant enzymes
UA80692C2 (en) Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer and inflammatory diseases
Yin et al. Diallyl disulfide inhibits the metastasis of type Ⅱ esophageal‑gastric junction adenocarcinoma cells via NF-κB and PI3K/AKT signaling pathways in vitro
EP3442564B1 (en) Composition of proenzymes for cancer treatment
ES2965358T3 (es) Tratamiento del cáncer
Wolny et al. Antiproliferative effect of valproic acid and 5, 7-dimethoxycoumarin against A2058 human melanoma cells
Zalavadiya et al. Bromelain's Properties and Therapeutic Applications: A Review
Huang et al. Diprivan attenuates the cytotoxicity of nitric oxide in cultured human bronchial epithelial cells
AU2016353539B2 (en) Proenzyme composition
KR100193983B1 (ko) 메실산 가벡세이트를 유효성분으로 함유하는 단백분해효소 억제제, 종양침윤 억제제, 종양전이 억제제, 종양성장 억제제 및 혈관신생 억제제
Potash Indole-3-carbinol and a Novel Derivative (OSU-A9) for Bladder Cancer Treatment A Senior Honors Thesis